Search Results - nazareno+paolocci

3 Results

Sort By:

Alkylsulfenyl Thiocarbonates as Precursors to Hydropersulfides

Unmet Need:According to a survey by the CDC, nearly 50% of Americans age 20 and up have some form of cardiovascular disease (see AHA). The management of cardiovascular diseases depends on the specific indication, and standard therapies include one or multiple of the following types of medications: blood thinners, ACE inhibitors, beta-blockers, calcium...

Published: 5/10/2024 | Inventor(s): John Toscano, Vinayak Khodade, Sahil Aggarwal, Nazareno Paolocci, Blaze Pharoah, Gizem Keceli, Kelsey Zhang

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Clinical and Disease Specializations > Oncology

Preventing Myocardial Loss and Sudden Death in Patients with Arrhythmogenic Cardiomyopathy via Rescuing of AIF/thioredoxin-2 Signaling

Unmet NeedAbout 400,000 to 460,000 people die each year from sudden cardiac death (SCD). Patients with Arrhythmogenic Cardiomyopathy (ACM) are at increased risk for heart failure and SCD triggered by exercise. Common ACM driver mutations occur in about 1 out of every 10,000 people. However, the physiological mechanisms that drive myocardial loss and...

Published: 5/9/2024 | Inventor(s): Stephen Chelko, Nazareno Paolocci, Gizem Keceli, Daniel Judge, Nunzianna Doti, Menotti Ruvo, Alessandra Monti, Nuria Amat, Peter Andersen

Keywords(s): Cardiac Arrest, Cardiovascular Diseases, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Cardiovascular > Cardiac Arrest, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

P75 Neurotrophin Receptor Antagonist for the Treatment of Acute and Chronic Cardiac Disease

Unmet Need / Invention Novelty: Hemodynamic stress during heart disease results in adverse remodeling and loss of function of the myocardial tissue. One mechanism that underlies this pathology is activation of the p75 neurotrophin receptors (p75NTR) in the heart. There is an unmet need for a therapeutic which blocks the p75 neurotrophin receptor in...

Published: 5/9/2024 | Inventor(s): Nazareno Paolocci, Ning Feng, Carlo Tocchetti, Cyrus Takahashi, Bruce Carter

Keywords(s): Antagonists/Inhibitors, Biologics, Cardiovascular Diseases, Disease Indication, Myocardial Infarction (MI), Non-novel, Peptide, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Cardiovascular > Acute Heart Failure